Active Filter(s):
Details:
The acquisition was triggered following the conclusion of a Phase 1 proof- of-mechanism study of investigational medicine TAK-062 (Kuma062) for the treatment of uncontrolled celiac disease.
Lead Product(s): TAK-062
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $330.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 26, 2020